CYP2D6*10基因多态性与泮托拉唑药动学关系研究

Study on the Relationship of CYP2D6*10 Gene Polymorphism with Pharmacokinetics of Pantoprazole

目的:研究泮托拉唑在不同CYP2D6*10基因型健康志愿者体内的药动学。方法:24名健康志愿者分为CC组、CT组、TT组;应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析CYP2D6*10基因型。受试者均口服泮托拉唑肠溶胶囊(40mg)后,采用高效液相色谱法测定血药浓度。结果:CC组、CT组、TT组的t1/2分别为(1.78±0.34)、(1.51±0.64)、(2.05±0.37)h,cmax分别为(3.20±0.82)、(3.29±0.74)、(3.13±0.79)mg/L,AUC0-12h分别为(11.18±3.94)、(11.37±4.66)、(14.31±4.77)mg·h/L。通过t检验,t1/2、cmax、AUC0-12h3种基因型之间的差异均无统计学意义(P>0.05)。结论:泮托拉唑药动学在个体间的差异与CYP2D6*10基因型可能不相关。

OBJECTIVE： To study the pharmacokinetics ofpantoprazole in healthy volunteers with different CYP2D6＊10 genotypes. METHODS： 24 healthy volunteers were divided into CC group, CT group and TT group; CYP2D6＊10 genotype was analyzed with polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP）. The subjects were given Pantoprazole enteric-coated capsules （40 rag） orally, and then the blood concentration of pantoprazole was determined by HPLC. RESULTS： Main pharmacokinetic parameters of CC group, CT group and TT group were as follows： 2 were （1.78 ± 0.34） h, （1.51 ± 0.64） h and （2.05 ＋ 0.37） h; Cm were （3.20 ± 0.82） mg/L, （3.29 ±0.74）mg/L and（3.13 ± 0.79） mg/L; AUC0-2h were （11.18 ± 3.94）mg.h/ L, （11.37 ± 4.66） mg.h/L and （14.31 ± 4.77） mg.h/L, respectively. After t-test, there were no statistical significance in differences of and AUC0 among three genotypes （P〉0.05）. CONCLUSIONS： The individual pharmacokinetics differences of pantoprazole may not be related to CYP2D6＊10 genotypes.